Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Mulling Once-a-Year COVID Booster for Elderly in FY2024
September 8, 2023
- MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
September 8, 2023
- LDP Lawmakers Deplore Reported GMP Issues at Sawai
September 8, 2023
- MHLW Plans to Consolidate Class 2 and 3 OTC Drugs
September 7, 2023
- Exact Sciences’ SaMD to Assess Breast Cancer Recurrence Risk Listed on Sept. 1
September 7, 2023
- Japan Eyes AI-Driven Drug Discovery Project for Cancer, Intractable Diseases
September 7, 2023
- Japan Unveils 2nd Package Strategy for SaMD
September 7, 2023
- Japan Healthcare Spending Renews Record with 46 Trillion Yen in FY2022
September 6, 2023
- Japan to Soon Start Taking Applications for Antibiotic Revenue Guarantee Program
September 6, 2023
- MHLW to Launch Working Group on Drug Supply Info on Sept. 7
September 5, 2023
- 23 Suspected Violations in Promotion Activities Reported in FY2022: MHLW
September 5, 2023
- Dispensing Pharmacy Chief Nabbed for Obstruction of Public Bid
September 4, 2023
- Japan Launches Agency for Infectious Disease Crisis Management
September 4, 2023
- Relief Claims OK’ed for 54 More Deaths after COVID Vaccination
September 4, 2023
- Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
- MHLW Rejigs Organization, Infectious Disease Control Team Boots Up
September 1, 2023
- Industry Requests Rewards for SaMDs that Help Doctors’ Workstyle Reform
September 1, 2023
- Japan to Decide on COVID Health Funding from October, Assuming Shift to Normalcy Next Spring: Minister
September 1, 2023
- MHLW Must Streamline Operations via DX, Improve Staff’s Work-Life Balance: Official
September 1, 2023
- 8 New Cases of Unintentional Xocova Use Among Pregnant Patients, Adding Up to 15
August 31, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…